Glenmark Pharma Stock Price News: Mumbai-headquartered Glenmark Pharmaceuticals’ shares faced selling pressure on Monday, shrugging off a one per cent surge in the Nifty50 amid hopes of GST rate cuts. The drug maker’s stock fell as much as 4.6 per cent to Rs 1,949 apiece on BSE. At 3 pm, the stock — traded with the symbol GLENMARK on exchanges BSE and NSE — was down 3.4 per cent at Rs 1,974.3 and down 3.5 per cent at Rs 1,974 apiece on BSE and NSE, respectively.
Meanwhile, headline indices Nifty 50 and Sensex rallied around one per cent each after the central government announced new GST reforms, set to be implemented by Diwali this year.
ALSO READ: PM’s GST Reforms: How Centre may make up for Rs 60,000 crore revenue loss
Glenmark Pharma Q1 FY26 Results | Top and bottom lines vs expectations
After the market hours on Thursday, Glenmark Pharma reported a consolidated net profit of Rs 46.8 crore for the April-June period, marking a fall of 86.2 per cent compared to the corresponding period a year ago owing to an exceptional loss of Rs 323.2 crore.
Its first-quarter revenue increased 0.6 per cent to 3,264.4 crore, according to a regulatory filing.
According to Zee Business research, the pharmaceutical company was expected to register a net profit of Rs 375 crore with revenue of Rs 3,513 crore for the first qurater of the current financial year.
Glenmark Pharma Q1 Earnings | How Mumbai-based drug maker fared operationally
The drug maker’s June-quarter earnings before interest, taxes, depreciation and amortisation came in at Rs 580.5 crore, decline of 1.3 per cent on a year-on-year basis.
Its margin — a key measure of profitability — contracted by 30 basis points (bps) to 17.8 per cent, according to the filing.
According to the research, the Mumbai-based company was estimated to register a quarterly EBITDA of Rs 651 crore.
The analysts had pegged its quarterly margin at 19 per cent.
Glenmark Pharma shares vs Nifty 50 vs Nifty Pharma
At the current level, the GLENMARK stock has risen 22.3 per cent so far in 2025, sharply outperforming a 4.9 per cent gain in the Nifty 50 and a 5.7 per cent decline in the Nifty Pharma.
ALSO READ: GST reduction may boost auto demand, job creation in India, says HSBC report
